You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RRMM

Showing 26 - 50 of 174
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed and/or Refractory Multiple Myeloma (RRMM) Trial in United States (TAK-981, Mezagitamab, Daratumumab and

Recruiting
  • Relapsed and/or Refractory Multiple Myeloma (RRMM)
  • Scottsdale, Arizona
  • +11 more
Jan 6, 2022

Multiple Myeloma Trial in United Kingdom (Pomalidomide, Dexamethasone, Cyclophosphamide)

Active, not recruiting
  • Multiple Myeloma
  • Belfast, United Kingdom
  • +20 more
May 24, 2022

Identify Barriers to Cellular Therapies for People With Plasma

Recruiting
  • Multiple Myeloma
  • Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM
  • +5 more
  • Basking Ridge, New Jersey
  • +6 more
Nov 6, 2023

Plasma Cell Myeloma Recurrent Trial in Australia, Chile (Isatuximab IV, Isatuximab SC, Dexamethasone)

Recruiting
  • Plasma Cell Myeloma Recurrent
  • Isatuximab IV
  • +3 more
  • Salt Lake City, Utah
  • +33 more
Jan 16, 2023

Multiple Myeloma Trial in Beijing, Jiang Su Province (Belantamab mafodotin)

Completed
  • Multiple Myeloma
  • Belantamab mafodotin
  • Beijing, China
  • +2 more
Feb 8, 2022

Relapsed/Refractory Multiple Myeloma Trial in Japan (ABBV-383)

Recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Kashiwa-shi, Chiba, Japan
  • +5 more
Jan 25, 2023

Relapsed or Refractory Multiple Myeloma Trial in China (SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone))

Recruiting
  • Relapsed or Refractory Multiple Myeloma
  • SVd (Selinexor+Bortezomib+dexamethasone)
  • Vd (Bortezomib+dexamethasone)
  • Hefei, Anhui, China
  • +33 more
Aug 14, 2022

Belantamab Mafodotin in Relapsed and/or Refractory Multiple

Recruiting
  • RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA
  • Belantamab mafodotin
  • Albacete, Spain
  • +61 more
Aug 2, 2022

Relapse Multiple Myeloma, Multiple Myeloma Trial in Brno, Ostrava, Praha (OPD5)

Withdrawn
  • Relapse Multiple Myeloma
  • Multiple Myeloma
  • Brno, Czechia
  • +2 more
Nov 17, 2021

Multiple Myeloma Trial in Chengdu (Selinexor, Thalidomide, Dexamethasone)

Not yet recruiting
  • Multiple Myeloma
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
May 13, 2021

Multiple Myeloma in Relapse, Refractory Multiple Myeloma Trial in Israel (ixazomib-pomalidomide-dexamethasone)

Recruiting
  • Multiple Myeloma in Relapse
  • Refractory Multiple Myeloma
  • Afula, Israel
  • +7 more
Jul 10, 2022

Multiple Myeloma Trial in Worldwide (bb2121, Daratumumab, Pomalidomide)

Active, not recruiting
  • Multiple Myeloma
  • bb2121
  • +8 more
  • Birmingham, Alabama
  • +59 more
Dec 13, 2022

POmalidomide Plus LoW Dose Dexa Efficacy in RRMM Patients Under

Completed
  • Relapse/Refractory Multiple Myeloma
    • Patra, Greece
      Ag.Andreas General Hospital
    May 10, 2021

    Multiple Myeloma Trial in Worldwide (Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib)

    Terminated
    • Multiple Myeloma
    • Melphalan flufenamide (Melflufen)
    • +3 more
    • Boston, Massachusetts
    • +15 more
    Mar 4, 2022

    Safety and Efficacy Trial in Suzhou (JWCAR129)

    Recruiting
    • Safety and Efficacy
    • JWCAR129
    • Suzhou, Jiangsu, China
      First Affiliated Hospital, Soochow University
    Dec 16, 2020

    Multiple Myeloma Trial in Worldwide (Belantamab mafodotin, Lenalidomide, Dexamethasone)

    Active, not recruiting
    • Multiple Myeloma
    • Belantamab mafodotin
    • +3 more
    • Birmingham, Alabama
    • +25 more
    Dec 9, 2022

    Plasma Cell Myeloma Trial in Worldwide (isatuximab SAR650984, Pomalidomide, Dexamethasone)

    Recruiting
    • Plasma Cell Myeloma
    • isatuximab SAR650984
    • +3 more
    • Little Rock, Arkansas
    • +83 more
    Aug 12, 2022

    PETHEMA-POMCIDEX Clinical Practice Guidelines for Treatment of

    Completed
    • Relapsed and Refractory Multiple Myeloma
      • Barcelona, Spain
      • +26 more
      Feb 4, 2021

      Plasma Cell Myeloma Trial in United States (Isatuximab SAR650984, Pomalidomide, Dexamethasone)

      Completed
      • Plasma Cell Myeloma
      • Isatuximab SAR650984
      • +2 more
      • Scottsdale, Arizona
      • +12 more
      Jul 8, 2021

      Multiple Myeloma Trial (Bela, Belamaf, Lenalidomide)

      Not yet recruiting
      • Multiple Myeloma
      • (no location specified)
      Jan 27, 2023

      Relapsed and/or Refractory Multiple Myeloma Trial (TAK-573, Pomalidomide, Bortezomib)

      Withdrawn
      • Relapsed and/or Refractory Multiple Myeloma
      • (no location specified)
      Jul 10, 2020

      Multiple Myeloma Trial in Worldwide (Pomalidomide and Dexamethasone)

      Completed
      • Multiple Myeloma
      • Pomalidomide and Dexamethasone
      • Linz, Austria
      • +21 more
      Aug 25, 2021

      RRMM Trial in Lishui, Wenzhou (CAR-T therapy in Relapsed/Refractory multiple myeloma)

      Unknown status
      • RRMM
      • CAR-T therapy in Relapsed/Refractory multiple myeloma
      • Lishui, Zhejiang, China
      • +2 more
      Nov 16, 2020

      Refractory Multiple Myeloma, Relapsed Multiple Myeloma Trial in San Francisco (Manufactured Anti-BCMA CAR-T cells, Fludarabine,

      Recruiting
      • Refractory Multiple Myeloma
      • Relapsed Multiple Myeloma
      • Manufactured Anti-BCMA CAR-T cells
      • +2 more
      • San Francisco, California
        University of California, San Francisco
      Jan 6, 2023

      Management Plan Material Utilization Among Pharmacists in Japan

      Not yet recruiting
      • Multiple Myeloma
      • No Intervention
      • (no location specified)
      May 22, 2023